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Genetic disorders of the skeleton encompass a diverse group of bone diseases differing in
clinical characteristics, severity, incidence and molecular etiology. Of particular interest are
the monogenic rare bone mass disorders, with the underlying genetic defect contributing
to either low or high bone mass phenotype. Extensive, deep phenotyping coupled with
high-throughput, cost-effective genotyping is crucial in the characterization and diagnosis
of affected individuals. Massive parallel sequencing efforts have been instrumental in the
discovery of novel causal genes that merit functional validation using in vitro and ex vivo
cell-based techniques, and in vivo models, mainly mice and zebrafish. These translational
models also serve as an excellent platform for therapeutic discovery, bridging the gap
between basic science research and the clinic. Altogether, genetic studies of monogenic
rare bone mass disorders have broadened our knowledge on molecular signaling
pathways coordinating bone development and metabolism, disease inheritance
patterns, development of new and improved bone biomarkers, and identification of
novel drug targets. In this comprehensive review we describe approaches to further
enhance the innovative processes taking discoveries from clinic to bench, and then backn.org August 2021 | Volume 12 | Article 7097111
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Frontiers in Endocrinology | www.frontiersito clinic in rare bone mass disorders. We highlight the importance of cross laboratory
collaboration to perform functional validation in multiple model systems after identification
of a novel disease gene. We describe the monogenic forms of rare low and high rare bone
mass disorders known to date, provide a roadmap to unravel the genetic determinants of
monogenic rare bone mass disorders using proper phenotyping and genotyping
methods, and describe different genetic validation approaches paving the way for
future treatments.Keywords: bone mass, monogenic bone disorders, gene variants, functional validation, drug discovery,
GEMSTONE, skeletal dysplasiaINTRODUCTION
Skeletal development is regulated by numerous genetic factors
that guide the growth, modeling and remodeling of skeletal
structures starting in early fetal development and continuing
throughout life. These processes are crucial for attainment of
normal height, skeletal patterning, bone shape, and mobility, but
also for maintenance of normal bone mass and fracture
resistance. Defects in the involved genes result in a large and
heterogeneous group of disorders, collectively called skeletal
dysplasias, in which the primary features are confined to the
skeleton. More than 460 different forms of skeletal dysplasia,
most of them monogenic, have been recognized (1). They are
estimated to affect approximately 1/5,000 children (2, 3), and can
have distinct clinical manifestations and course. Clinical
outcomes range in severity from neonatal lethality to only mild
growth retardation, deformity or fracture risk. Diagnosis is based
on growth pattern and other clinical characteristics, skeletal
imaging, bone density testing, biochemical diagnostics, and
genetic tests. Although the genetic basis has been described
and mutations in the responsible genes identified in a
significant proportion of these conditions, for several distinct
skeletal dysplasia phenotypes the genetic cause is still not
known (1).
Within this large group of genetic skeletal disorders,
monogenic disorders affecting bone mass comprise an
expanding subgroup (1, 4). This includes disorders with low
bone mass and skeletal fragility, and disorders leading to
increased bone mass, both commonly associated with extra-
skeletal complications (5, 6). Due to significant variability in
severity, diagnosis can be challenging. Importantly, the
underlying molecular genetic mechanisms for these disorders
remain inadequately explored and, in several entities, the
causative genetic defect, and underlying cellular and molecular
pathophysiology are still uncharacterized.
The various skeletal dysplasia delineated to date have provided
important information about the molecular pathways governing
skeletal health both in these conditions and in the general
population, underscoring the significance of new gene
discoveries not only for the individuals affected by the
monogenic rare bone mass disorder, but also more widely to
the musculoskeletal research field (7). Indeed, the large wealth of
data generated from monogenic and polygenic bone massn.org 2disorders, frailty and other musculoskeletal traits, have led to
establishment of GEMSTONE, a COST action (CA18139; https://
cost-gemstone.eu) set up to bring together multidisciplinary
researchers actively involved in the musculoskeletal field. The
aim of GEMSTONE is to translate the genetic discoveries into
meaningful clinical applications and personalized medicine,
discussed in more detail in Koromani et al., “GEnomics of
MusculoSkeletal traits TranslatiOnal NEtwork (GEMSTONE):
origins, rationale, organization and prospects” (8).
This paper aims to provide an overview of the presently
known monogenic disorders of low and high bone mass, and to
provide a roadmap to move forward in identifying and
characterizing novel genetic forms, with the aim of utilizing
these discoveries to develop novel therapies. We have elucidated
the various steps of this process: deep phenotyping of the patient
with a potentially novel skeletal condition, genetic evaluation
and discovery of the causative gene defect, functional in vitro
and in vivo validation, and potential approaches for novel
drug discoveries.THE SPECTRUM OF MONOGENIC BONE
FRAGILITY DISORDERS
Origins of Bone Fragility
The composition, amount and microarchitecture of human bone
tissue determines its fracture load and resistance to bending and
torsional forces. Increased bone fragility with low bone mass is
either acquired (most commonly secondary to medications e.g.,
corticosteroids, aging, immobility, low body weight, nutritional
deficiencies, systemic disorders e.g., chronic inflammatory
conditions, endocrine pathology), or genetic, or a multitude of
both (7, 9). Relevant to GEMSTONE, more specificallyWorking
Group 3 (Monogenic conditions – human knockout models),
are the rare monogenetic forms of low and high bone mass, that
result from mutations in genes regulating bone composition and
function of essential proteins required for type I collagen
assembly, osteoblastic bone formation, bone mineralization
and osteoclastic bone resorption. The advancements in
sequencing methods, especially massively parallel sequencing,
have enabled identification of many new monogenic disorders
caused by defects in genes that encode proteins in various
metabolic pathways (10).August 2021 | Volume 12 | Article 709711
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Osteogenesis imperfecta (OI) is, by far, the most common
heritable cause of increased bone fragility. It is characterized by
fractures, often at a young age, low bone mass, deformities and
variable short stature, but also by a number of extra-skeletal
features such as blue sclerae, dental problems, skin and joint
laxity, and a hearing deficit (11). Currently, more than 20 distinct
genetic entities have been grouped under this diagnosis (12).
They have in common that they all, via different mechanisms,
affect the quality or quantity of type I collagen, the main protein
component of the skeleton. However, the spectrum of
mechanisms ultimately leading to defective collagen assembly
in the extracellular matrix has expanded considerably recently,
necessitating several revisions in classifications (13, 14). In most
cases, studies on disease mechanisms in vitro and in animal
models have indicated defects in collagen secretion and
structure, procollagen transport, folding, post-translational
modification, processing and crosslinking. By contrast, some
forms of OI are associated with impaired mineralization
(IFITM5, SERPINF1), or defective osteoblast differentiation
and function (SP7, WNT1), rather than a direct defect in type I
collagen deposition (13, 15).
Clinically, the variability of presentation and genotypes has
made it difficult to differentiate between OI and so-called
primary osteoporosis, which is why we present a spectrum of
these entities (Table 1). For example, non-collagen pathways
associated with bone fragility include the osteoblastic WNT
signaling pathway (e.g., WNT1, LRP5) which regulates bone
formation and the OPG/RANKL system (e.g., TNFRSF11A)
which regulates osteoclast activity. Various forms of OI and
primary osteoporosis are still incompletely understood; the
extremely rare conditions associated with bone fragility
continue to hold secrets to our understanding of bone fragility
which future research will need to explore (13, 15).
While not commonly included in bone fragi l i ty
classifications, we have included pure demineralization
disorders caused by a lack of bone mineral supply (genetic
forms of rickets/osteomalacia) and osteopetrotic conditions
that increase the density of bone mineral and fracture risk,
discussed further below (Table 1).
High Bone Mass Disorders
Several rare genetic disorders with skeletal effects, collectively
termed osteopetroses and sclerosing bone dysplasias, are
associated with a generalized increase in BMD. These disorders
can be divided into those in which bone resorption is suppressed,
those in which bone formation is enhanced, and those with a
disturbed balance between formation and resorption (Table 1).
Of the currently described 462 genetic disorders of the skeleton,
45 are characterized by osteosclerosis or osteopetrosis,
implicating 40 genes (1).
The osteopetroses are rare genetic conditions of reduced
osteoclastic bone resorption. Defective bone remodeling
induces skeletal sclerosis and abnormally dense, and therefore
brittle bones. Osteopetrosis is classified by clinical severity
(Table 1). Severe neonatal or infantile forms have the worstFrontiers in Endocrinology | www.frontiersin.org 3prognosis (16), while CLCN7 variants causing osteopetrosis late‐
onset form type 2 (OPTA2) (formerly autosomal dominant type
II osteopetrosis (ADOII) have a varied clinical phenotype,
including asymptomatic forms (17). These mildest forms can
be detected as an incidental radiographic finding (18).
Pycnodysostosis is caused by defective enzymatic degradation
of organic bone matrix, due to autosomal recessive mutations in
the gene encoding cathepsin K. Secreted by osteoclasts, cathepsin
K cleaves type I collagen (19). The characteristic bone dysplasia
includes skull deformities with micrognathia, short stature,
dental caries, and abnormally dense, brittle bones (20–22).
Understanding of pycnodysostosis prompted development of a
novel class of anti-resorptive therapy (e.g., odanacatib) (23).
By contrast, the sclerosing bone dysplasias are associated with
increased bone strength and resistance to fracture due to
increased bone formation (Table 1). Loss-of-function (LoF)
SOST variants cause sclerosteosis, a rare condition of excessive
bone overgrowth (24); a 52-kb deletion located approximately
35-kb downstream of SOST is thought responsible for the milder
phenotype of van Buchem’s disease (25, 26). Sclerosteosis causes
tall stature, mandible enlargement, torus palatinus and
mandibularis which complicate tooth extractions (27, 28).
Calvarial overgrowth can lead to compression of cranial
nerves, particularly facial nerves, sometimes from infancy (27).
The underlying SOST gene codes for Sclerostin, an inhibitor of
WNT signaling that binds to LRP5/LRP6 co-receptors to
decrease osteoblastic bone formation. LoF SOST mutations
result in increased osteoblastic bone formation. Similarly,
variants in LRP5 and LRP6 which prevent sclerostin binding
can lead to HBM (29, 30). More recently a novel, likely LoF
variant in the DNA-binding domain of SMAD9 was reported in
three kindreds with HBM, displaying features of mandible
enlargement, torus palatinus and torus mandibularis (31).
Unusually, a feature which seems to be common to these
sclerosing bone dysplasias is an inability to float!CAREFUL PATIENT PHENOTYPING IS
KEY TO DISEASE DISCOVERY
It is evident that the spectrum of abnormal skeletal phenotypes is
wide, highlighting the importance of a thorough phenotypic
evaluation to determine disease characteristics and the extent
of skeletal and extra-skeletal manifestations in patients with
a suspected rare bone disease. A detailed patient history is
essential and should provide information regarding growth and
development, previous and concurrent illnesses including any
medical treatment, dental health, skeletal and non-skeletal
symptoms, physical activity and potential restricted mobility,
and other lifestyle factors. Family history is important, both in
adults and children. A fracture history should cover all fractures
sustained from childhood to present age, and must be
accompanied by age at fracture, fracture site, fracture
mechanism (low, moderate or high-energy trauma), treatment,
and fracture healing duration (1).August 2021 | Volume 12 | Article 709711
TABLE 1 | Bone fragility conditions with low and high bone mass; the gene defects, function and clinical characteristics.
Symptoms*
Mild form, Clinical type I
Perinatal lethal, Clinical type II
Severe form, Clinical type III
Moderate form, Clinical type IV
Clinical types V; and III (atypical type 6)
Clinical type III
Clinical types II, III, IV
Clinical types II, III
Clinical types II, III
nk Clinical type III
nk Clinical types III, IV
Bruck Syndrome Type 1
Clinical type IV
Clinical Type III
Clinical type I, III, IV





Clinical type III, IV
Clinical type III, overlap with Stuve-Wiedemann
syndrome
n Clinical type III, IV
Clinical type III


















































LoF Collagen alpha-1(I) chain
Collagen alpha-2 (I) chain
Collagen synthesis
610967 AD IFITM5 GoF Interferon-induced Transmembrane
protein 5 (BRIL)
Mineralization
613982 AR SERPINF 1 LoF Pigment epithelium-derived factor (PEDF) Mineralization
610854 AR CRTAP LoF Cartilage-associated protein (CRTAP) Collagen modification
610915 AR LEPRE1
(P3H1)
LoF Leucine proline enrichedproteoglycan1 /
Prolyl 3-hydroxylase 1 (P3H1)
Collagen modification
259440 AR PPIB LoF Cyclophilin B (CyPB) Collagen modification
613848 AR SERPINH1 LoF Serpin peptidase inhibitor, clade H,
member 1/heat shock protein 47
Collagen folding and cross-l
610968
259450
ARAR FKBP10 LoF Peptidyl-prolyl cis-transisomerase
FKBP10
Collagen folding and cross-l
613849 AR SP7 LoF Zinc-finger transcription factor, Osterix Osteoblast differentiation an
maturation
112264 AR BMP1 LoF Bone morphogenic protein1/ procollagen
C proteinase
Collagen processing










CREB3L1 LoF Old astrocyte specificallyinduced
substance (OASIS)
ER UPR response, ER-Golg
trafficking, cleavage stimulat
ceramide









46, Member A (FAM46A)
BMP signaling
301014 XR MBTPS2 LoF Site 2 protease (S2P) Golgi Regulated intramembr
proteolysis
607783 AR MESD LoF Mesoderm development LRP chaperon WNT signaling






TABLE 1 | Continued
Symptoms*
Clinical type III





Calvarial doughnut lesions with bone fragility without







Singleton-Mertin dysplasia Type 1
Singleton-Mertin dysplasia Type 2
Spinal muscular atrophy with congenital bone
fractures-1 (SMABF1)
Spinal muscular atrophy with congenital bone
fractures-2 (SMABF2)
Familial expansile osteolysis (FEO)
Juvenile Paget’s Disease (PDB2)








































Condition OMIM Inheritance Gene Mutation Protein Function
618788 AR CCDC134 LoF Coiled-coil domain containing 134 MAPK pathway








Low density lipoprotein receptor 5
(LRP5)
WNT signaling
300910 XL PLS3 LoF Plastin 3 Formation of F-actin bundles
609220 AR PLOD2 LoF Telopeptide lysyl hydroxylase Collagen crosslinking
126550 AD SGMS2 LoF Phosphatidylcholine:ceramide
Cholinephosphotransferase 2
Mineralization
112240 AD P4HB LoF Protein disulfide-isomerase Catalyzes rearrangement of disulfide
bonds
605822 AR XYLT2 LoF Xylosyltransferase 2 Proteoglycan biosynthesis
166260 AD ANO5 LoF Anoctamin-5 Unclear (chloride channel)
231070 AR GORAB LoF RAB6-interacting golgin Unclear
612940 AR PYCR1 LoF Pyrroline-5-carboxylate reductase 1,
mitochondrial
Unclear (Prolin biosynthesis)
182250 AD IFIH1 GoF Interferon-induced helicase C domain-
containing protein 1
Unclear (Antiviral innate immunity)
616298 AD DDX58 GoF Antiviral innate immune response
receptor RIG-I
Unclear (antiviral innate immunity)
616866 AR TRIP4 LoF Activating signal cointegrator 1 Unclear (transcription coactivator)
616867 AR ASCC1 LoF Activating signal cointegrator 1 complex
subunit 1
Unclear (DNA damage repair)
Osteolysis group 174810
602080








LoF Matrix metalloproteinase 2Matrix
metalloproteinase 14
Unclear (collagenolysis)
102500 AD NOTCH2 GoF Neurogenic locus notch homolog protein
2




ARAD TNSALP LoF Tissue non-specific alkaline phosphatase Mineralization
307800 XL PHEX LoF Phosphate-regulating neutral
endopeptidase PHEX
Renal phosphate wasting
193100 AD FGF23 GoF Fibroblast growth factor 23 Renal phosphate wasting
TABLE 1 | Continued
Symptoms*
Hypophosphazaemia, ARHR1
Hypophosphataemia, ARHR2, overlap with GACI1
Hypophosphataemia with hypercalciuria, part of
Dent’s complex (XLRHR)










la Severe neonatal or infantile form, and fractures
(OPTB1)
la Severe neonatal or infantile form, and fractures
(OPTB4)
Infantile form and fractures, with nervous AR system
involvement (OPTB5)
la Severe neonatal or infantile form (OPTB8)
n, Intermediate form, and tendency to fracture (OPTB2)
n, Osteoclast poor osteopetrosis, and fractures
(OPTB7)







































cunaCondition OMIM Inheritance Gene Mutation Protein Function
241520 AR DMP1 LoF Dentin matrix acidic phosphoprotein 1 Renal phosphate wasting
613312
208000
AR ENPP1 LoF Ectonucleotide pyrophosphatase/
phosphodiesterase family member 1
Renal phosphate wasting
300554 XL CLCL5 LoF H(+)/Cl(-) exchange transporter 5 Renal phosphate wasting
241530 AR SCL34A3 LoF Sodium-dependent phosphate transport
protein 2C
Renal phosphate wasting





XL OCLR LoF Inositol polyphosphate 5-phosphatase
OCRL
Renal phosphate wasting
264700 AR CYP27B1 LoF 25-hydroxyvitamin D-1 alpha
hydroxylase, mitochondrial
Calcitriol synthesis
600081 AR CYP2R1 LoF Vitamin D 25-hydroxylase Calcitriol synthesis
277440 AR VDR LoF Vitamin D3 receptor Calcitriol receptor
600785 AR unknown LoF Vitamin D response element-binding
protein
Vitamin D response element
AD CYP3A4 GoF Cytochrome P450 3A4 Vitamin D catabolism





AR TCIRG1 LoF T-cell, immune regulator 1, H+
transporting, lysosomal subunit A3 of V-
ATPase pump
Acidification of the resorption
602727
611490
AR CLCN7 LoF Chloride Channel Acidification of the resorption
259720
607649
AR OSTM1 LoF Osteopetrosis associated
transmembrane protein 1
b-subunit for CLC-7
615085 AR SNX10 LoF Sorting Nexin 10 Acidification of the resorption
602642
259710










259710 AR CLCN7 Partial LoF Chloride Channel Acidification of the resorption
259700
611497
AR PLEKHM1 LoF Pleckstrin homology domain containing,
family M (with RUN domain) member 1
Vesicular trafficking
TABLE 1 | Continued
Symptoms*
Intermediate form with renal tubular acidosis, and
fractures (OPTB3)
Osteopetrosis with ectodermal dysplasia and
immune defect
Moderate form with defective leucocyte adhesion
(LAD3)
Late-onset osteopetrosis, and fractures (OPTA2,




















































Condition OMIM Inheritance Gene Mutation Protein Function
259730
611492
AR CA2 LoF Carbonic anhydrase II Intracellular acidification
300301 XL IKBKG LoF Inhibitor of kappa light polypeptide gene












guanine nucleotide exchange factor 1
166600 AD CLCN7 Dominant
negative
effect
Chloride Channel Acidification of the resorption lacun
265800 AR CTSK LoF Cathepsin K Collagen degradation










LoF LEM domain-containing 3
300373 XL(OSCS) WTX LoF Wilms tumour gene on the X
chromosome
WNT signaling suppression
224300 AR SLC29A3 LoF Solute carrier family 29 (nucleoside
transporter)
Osteoclast differentiation and funct
269500 AR SOST LoF Sclerostin Osteoblast WNT signaling inhibitor
239100 AR SOST Reduced
function
Sclerostin Osteoblast WNT signaling inhibitor
604270 AD & AR LRP4 LoF Low-density lipoprotein-related receptor 4 Impaired sclerostin-LRP4 interactio
603506 AD LRP5 GoF Low-density lipoprotein-related receptor 5 Osteoblast cell membrane co-
receptor regulating WNT signaling
awaited AD LRP6 GoF Low-density lipoprotein-related receptor 6 Osteoblast cell membrane co-
receptor regulating WNT signaling
awaited AD SMAD9 LoF SMAD family member 9 Inhibits BMP dependent target gen
transcription to reduce osteoblast
activity
123000 AD ANKH GoF Homolog of mouse ANK Osteoclast-reactive vacuolar proton
pump
218400 AR GJA1 LoF Gap junction protein alph‐1 Osteoclast-reactive vacuolar proto
pumpi
n
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Frontiers in Endocrinology | www.frontiersin.org 8Careful phenotyping includes routine physical examination, with
attention for the existence of extra skeletal signs of OI such as
blue sclerae, dental abnormalities, hyperlaxity of skin and joints,
and signs of secondary diseases like Cushing syndrome, thyroid
disease or malnutrition. Laboratory investigations should include
relevant parameters to determine calcium-phosphate
homeostasis and to exclude secondary causes of osteoporosis.
The extent of tests depends on the patient’s age and clinical
manifestations, and can include e.g., serum calcium, phosphate,
alkaline phosphatase, 25-hydroxyvitamin D, parathyroid
hormone, thyroid function, gonadal hormones, prolactin,
glucose, complete blood count, erythrocyte sedimentation rate,
C-reactive protein, kidney and liver function, ferritin, celiac
serology, urinary calcium excretion, and bone turnover
markers. Further analyses should include appropriate
radiological investigations (plain radiography, CT, MRI,
radionuclide bone scintigraphy), and bone density assessment
by DXA (Table 2). In selected cases, a transiliac bone biopsy may
help in diagnosis but requires analysis by an experienced
histopathologist with very specific bone expertise. Repeat
measurements of BMD may indicate whether low bone mass is
due to inadequate bone accrual or increased bone loss.
In a clinical setting, the means to obtain detailed information
about the bone tissue characteristics are usually limited.
However, if a novel skeletal phenotype with low or high bone
mass is suspected, several research tools can be used to determine
the bone characteristics in peripheral (pQCT, HRpQCT) or
central (QCT) sites. Furthermore, a double-labelled, transiliac
bone biopsy can be analysed using multiple techniques. The
standard histological and histomorphometric evaluations can be
complemented with back-scattering electron imaging, Raman
microspectroscopy and even immunohistochemistry. In
addition, a transiliac bone biopsy provides the opportunity to
obtain a bone marrow sample for mesenchymal stem cell (MSC)
and osteoblast cultures. In case of HBM disorder it can be hard to
obtain a bone biopsy. Skin fibroblasts, retrieved from the affected
individual either at the bone biopsy site or, more commonly,
from the forearm skin, are also widely used in various
functional studies.
Altogether, rigorous phenotyping remains an imperative step
in disease discovery and interpretation of disease causation. To
this effect, GEMSTONE has recognized the importance of careful
phenotyping, setting up Working Group 2 (‘Phenotyping’)
aimed at disentangling the complex heterogenous components
of monogenic and polygenic bone disease into more well-defined
processes. A detailed review of this is described elsewhere (32).GENETIC APPROACHES TO
GENE DISCOVERIES
In individuals with a suspected monogenic disorder of increased
or decreased bone mass, the approach presented in the flowchart
could be used to identify the genetic cause (Figure 1).
If the clinical diagnosis is clear, the genetic analysis can be
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Formosa et al. Discoveries in Bone Mass Disorderson the size and the number of genes, Sanger sequencing may
be appropriate. However, in most cases high-throughput
sequencing using a gene panel will be more cost- and labor-
efficient. For the analysis of genes involved in OI, several gene
panels are commercially available. For cases with increased
bone mass, availability is more limited but often the relevant
genes are included in wider skeletal dysplasia gene panels.
In addition, academic groups have developed gene panels for
research purposes.
Since the number of gene panels is ever increasing and
patients with less severe phenotypes are subjected to genetic
investigations, clinicians often face difficulties interpreting
genetic results. A general and reasonable recommendation is to
follow the American College of Medical Genetics and Genomics
(ACMG) guidelines (33) and only report those variants found to
be either ‘likely pathogenic’ or ‘pathogenic’ (ACMG scores 4 and
5, respectively). For variants of unknown significance (ACMG =
3) the clinical significance remains uncertain and further work
may be required to confirm or refute pathogenicity of the variant.
Sometimes, analyses of family members can help to identify
whether a variant segregates with the phenotype. In researchFrontiers in Endocrinology | www.frontiersin.org 9settings, it would be optimal to set up a “rapid throughput
screening pipeline” to help prioritize the most interesting
potentially causal variants, which might be carried forward for
functional analyses.
A negative genetic screening result might indicate the
involvement of a currently unknown disease gene, as such
genes are obviously not included in established gene panels.
An exome-wide analysis starting from data generated by whole
exome sequencing (WES) or whole genome sequencing (WGS),
assessing all genes in the human genome, may offer an
opportunity to identify these novel genes and/or gene variants.
However, this approach, as well as the use of extended gene
panels, will result in the identification of a large number of gene
variants, necessitating variant filtering and variant prioritization
in order to end up with a short list of putative causal variants.
A plethora of filtering steps can be used for WES and WGS
data analyses. First degree relatives share 50% of their genome.
Thus, inclusion of other affected and non-affected relatives from
an extended family can help eliminate the shared benign genetic
variation shifting the focus on causal gene variants. This is a
pertinent step when dealing with the wealth of data generatedTABLE 2 | Tools and relevant clinical outcomes to be considered for careful skeletal phenotyping in patients with a skeletal phenotype.
Tool Phenotypic information
Clinical evaluation • Age at onset?
• Abnormal height and weight?




• Dental or oral abnormalities?
• Neurological manifestations?
• Hearing and/or visual loss?*
• Pain (back, bone)?
• Muscle weakness?
• Cutaneous lesions (e.g., fibrous dysplasia, mosaic RASopathies)?
• History or signs of systemic conditions influencing bone?
• Other extra-skeletal manifestations?
Biochemistry • Abnormal bone mineral homeostasis (calcium, phosphate, alkaline phosphatase, Vitamin D, Parathyroid hormone?
• Abnormal bone turnover?
• Endocrine or renal disturbances?
• Signs of secondary skeletal fragility (e.g., celiac disease, chronic inflammation)
Radiography • Abnormal bone texture (e.g., fibrous dysplasia, sclerosis)?
• Abnormal bone modeling?
• Evidence for skeletal dysplasia?
• Spinal compression fractures?
• Scoliosis, other spinal deformity?
• Abnormal cortical/calvarial thickness?
• Skeletal deformities?
• Abnormal bone maturation (in children)?
• Signs of nerve compression?
Bone density
DXA • Abnormal bone mineral content and BMD?
• Vertebral fractures (lateral spine, possible with some DXA machines)?
pQCT & HRpQCT • Bone characteristics at peripheral sites (in research settings)?
QCT • Bone characteristics of vertebrae (in research settings)?
Transiliac bone biopsy (double labeled) • Abnormal bone histomorphometry (structure)?
• Abnormal mineralization density (BMDD)?
• Abnormal bone cell proportions?*Consider formal audiometry and visual field assessment.August 2021 | Volume 12 | Article 709711
Formosa et al. Discoveries in Bone Mass Disordersfrom high-throughput sequencing. Contrary to the family-based
approach, incorporation of unrelated patients sharing the
phenotype should be done with caution. The genetic basis of
phenotypically similar monogenic conditions can be
heterogeneous, and assuming a shared disease-causing geneFrontiers in Endocrinology | www.frontiersin.org 10variant in all similarly affected individuals may well result in
the exclusion of the true causative variant.
The presence of variants in adult population databases such as
gnomAD (34) with a frequency above a selected threshold can
serve as a criterion for exclusion of these variants. According toFIGURE 1 | Flowchart for identifying the underlying genetic cause in disorders with increased or decreased bone mass. Affected individuals, either as isolated cases
or as part of a family study, are subjected to genetic testing in the form of targeted sequencing (using Sanger or high-throughput sequencing of candidate genes), or
WES/WGS, with the latter possibly undergoing prior linkage analysis to define loci that are shared by affected relatives and thus likely to harbour the causal gene(s).
Sequential filtering steps are applied to narrow down the extensive list of gene variants to a few variants that based on database and literature searches are most
likely to explain the disease. Shortlisted gene variants are functionally validated using in vitro cell work or in vivo animal models.August 2021 | Volume 12 | Article 709711
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directly to dismiss a variant as disease-causing. Furthermore, as
shown in Figure 2, reducing this threshold to 0.1% is acceptable,
as it is unlikely to result in a high risk of missing the relevant
variant, especially in autosomal dominant diseases. Short
insertions or deletions (indels) need special attention, because
although they are often predicted to cause LoF, the variant calling
algorithms are not as reliable as for single nucleotide variants
(SNVs) (36). For further selection, functional predictions for the
variants and/or current knowledge regarding gene function must
be taken into account. Many bioinformatics tools are available
for pathogenicity prediction of variants, such as Sorting
Intolerant From Tolerant, SIFT [(37) (https://sift.bii.a-star.edu.
sg/), Polymorphism Phenotyping v2, PolyPhen-2 (38) (http://
genetics.bwh.harvard.edu/pph2/], Combined Annotation
Dependent Depletion, CADD (39) (https://cadd.gs.washington.Frontiers in Endocrinology | www.frontiersin.org 11edu/), and Variant Effect Predictor, VEP (35) (https://useast.
ensembl.org/Homo_sapiens/Tools/VEP), and for linking the
variants with disorders by matching the clinical phenotypes as
defined by HPO (human phenotype ontology) terms (40). In
order to check whether other variants in the same gene have been
found somewhere in the scientific community, data can be
uploaded to GeneMatcher (41) (https://genematcher.org).
When assessing the relevance of genes in a candidate variant
list, one can integrate information from several resources. Some
examples are the Musculoskeletal Knowledge Portal (42) (http://
mskkp.org/), which provides a search engine for the results of
genome-wide association studies (GWAS) on bone phenotypes,
and the International Mouse Phenotyping consortium, IMPC
(43) (www.mousephenotype.org) to consult bone phenotypes of
knock-out mice. As the number of new gene discoveries
increases rapidly in low and high bone mass disorders,FIGURE 2 | Allele frequencies of LoF variants in the OI database. The figure displays all variants, and their allele frequencies, reported to the OI database which is
contained within the Leiden Open Variation Database (LOVD). Because the LOVD also contains benign variants, we have chosen to use LoF variants as a proxy for all
pathogenic variants. As is shown, pathogenic variants are not only very rare in dominant OI genes, but they are also very rarely found in recessive OI genes. *Number
of unique LoF variants in OI genes reported in the LOVD. **Genes with reported LoF variants in LOVD. Note that not all known OI genes have LoF variants, as
annotated by VEP (35), reported in LOVD.August 2021 | Volume 12 | Article 709711
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assessment process. Filtering of variants to only one or very
few potentially disease-causing variants should be first validated
by Sanger sequencing or other genotyping methods, followed by
appropriate functional studies, in vitro or in vivo, to validate the
disease causality of the selected variant.
Compared to the genome-wide approach, WES is currently a
more money and time saving option in terms of data storage and
data analysis. However, as the costs of DNA sequencing are
rapidly decreasing, WGS is becoming increasingly affordable,
even within a clinical setting. One can use the obtained data as a
virtual WES analysis by only looking at the coding parts of the
genome. A very important advantage of WGS is that all genes are
in general completely covered with relatively even coverage,
unlike WES which requires an additional step of DNA capture
that results in incomplete and uneven coverage of some genes.
Furthermore, WGS allows for structural variant analysis (44) and
opens up possibilities to gain insights into the involvement of
non-coding parts of the human genome.
As described, filtering of identified variants by WES is already
a difficult process which becomes even more challenging when
using WGS data. The number of variants increases exponentially
and the development of tools for validation of variants in non-
coding areas is currently one of the most challenging aspects of
genetic research. Copy number variant (CNV) detection,
although possible from WGS data, is limited with the current
short-read technology. However, long-read massive sequencing
such as that provided by PacBio or Oxford Nanopore, may
become available for clinical applications in the near future.
Germline variants in microRNAs and long non-coding RNAs
should also be kept in mind as they have been reported as an
underlying cause in a few skeletal disorders (45).
If no variant is identified byWES orWGS that can reasonably
explain the patient’s high or low bone mass phenotype, it may be
worth exploring patterns of gene expression using RNAseq
approaches. In this way, splice variants far from the canonical
splice-site can be detected, as well as monoallelic expression.
Also, total absence of a given transcript or appearance of a new,
potentially rare, alternative transcript unique to the patient’s
RNA and absent in control samples, provides strong evidence for
the involvement of the gene in disease pathogenesis. Ideally, one
would choose a single-cell approach and access bone cells to
obtain total RNA, which is understandably, not always feasible.
Instead, proxy tissues must often be used, such as lymphocytes or
skin fibroblasts. RNAseq is becoming quite popular as a second
line tool for gene identification and some nice examples of new
pseudo-exons due to deep intronic variants have been identified
in this way (44). However, methods are relatively expensive,
technically demanding and require specialized analysis.
Finally, a note about GWAS. It is important to understand
that in general such studies do not serve as tools for gene
discovery in monogenic diseases. GWAS performed at the
population level using large cohorts, have been very powerful
in defining the polygenic basis of BMD. They have been crucial
in highlighting pathways and genes involved in the regulation of
bone mass and fracture susceptibility. In many instances, theFrontiers in Endocrinology | www.frontiersin.org 12same gene, with rare penetrant variants causing a monogenic
BMD phenotype, has been associated with common variants
conferring susceptibility for the polygenic inheritance of BMD
(7, 46). The paradigm of this is LRP5, a gene responsible for
several monogenic conditions including HBM and osteoporosis-
pseudoglioma syndrome, but also the locus of genome-wide-
significant SNVs strongly associated with hip and spine BMD
(47, 48). Nevertheless, this does not apply to all genes underlying
monogenic skeletal dysplasias. GWAS results may soon lead to
the development of a tool to calculate a polygenic risk score
(PRS) for any given individual, allowing for prediction of the risk
for abnormal bone mass and possibly fracture risk, based on an
individual’s combination of susceptibility variants (49). While
this is still not a clinically available application, there will
probably be a time when we can combine PRS and rare variant
scrutiny through WES or WGS to gain precision in genetic
diagnosis of high or low bone mass phenotypes.VALIDATION OF GENETIC FINDINGS
Identifying the Best In Vitro Model
A fast and simple approach to functionally validate novel
candidate SNVs is through cell-based in vitro/ex vivo studies.
Experiments should be designed according to the type of
identified gene variant, the disease inheritance model, gene
expression levels and the associated protein function. Use of
appropriate cell lines is fundamental in recapitulating the
observed phenotype seen in affected individuals. Primary bone
cells harbor numerous advantages since they provide insight into
the function of previously unknown genes and can also be used
to investigate the defective cells’ function in comparison to that
exhibited by otherwise ‘healthy’ cells. For instance, primary
osteoblast cultures retrieved from a type VI OI patient with a
novel de novo dominant IFITM5 mutation, revealed that the
defective IFITM5 resulted in a reduced SERPINF1 expression
during cell differentiation, decreased type I collagen expression
and secretion, and induced mineralization defects. Type VI OI is
typically caused by recessive null mutations in SERPINF1.
However, findings supported the relationship between the two
genes and highlighted their role in different OI types and bone
mineralization (50). Moreover, rescue experiments have proved
to be an effective tool in recovering protein function,
complementing the results obtained in gene manipulation
studies (51).
Unfortunately, access to bone biopsies remains a challenge
and further complicates the limited availability of abnormal
tissue. To overcome this difficulty, induced pluripotent stem
cells (iPSCs) derived from patient fibroblasts can be
reprogrammed to differentiate into bone cells, reproducing the
disease model of interest (52–54). Moreover, if patient samples
are unavailable, cell lines modified by genetic engineering
techniques (such as CRISPR/Cas9) can be applied for
validation studies. Immortalized primary cells (from humans
or mice) such as osteoblasts (bone-forming cells e.g., hFOB),
mechanosensing osteocytes (e.g., ocy454, MLO-Y4), osteoclastsAugust 2021 | Volume 12 | Article 709711
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MSCs (precursors of osteoblasts); and cancer-derived (i.e.,
osteosarcoma cells [e.g., SaOS2, MG-63], or osteolytic [e.g.,
PC-3]) cell lines or adipose tissue-derived stem cells can be
utilized. Next, it is necessary to simulate the pathological
phenotype by generating or introducing the genetic
abnormality in the selected cells. The best way to achieve this
is to disrupt gene function and analyze cell function. It is crucial
to assess the steady state levels of the protein encoded by the
mutated gene, as well as the effect of the variant on protein
function. Aberrant protein function, possibly complete ablation,
is expected for LoF and missense variants. Researchers can
experimentally reduce gene expression at the translational level
using RNAi (knockdown) (55) or interrogate gene function by
completely and permanently silencing it through CRISPR/Cas9
genome editing (knockout) (56). Alternatively, identified gene
variants (such as SNVs, and indels) can be introduced in
plasmids expressing the gene of interest using site-directed
mutagenesis (SDM) or CRISPR-directed gene editing, followed
by transfection in specific cell types. Indeed, Collet et al. (2018)
demonstrated the pathogenicity of several LRP5 missense
variants following SDM that led to diminished luciferase
activity due to reduced activation of canonical WNT signaling
(57). Similarly, different PHEX variants identified in X-linked
hypophosphatemic rickets, both splicing and de novo mutations,
were introduced in minigene constructs by SDM and
functionally confirmed by gene expression profiling (58) and
evaluation of protein stability (59).
Finally, once cells are genetically modified, several tests may
be applied according to the expected pathogenic phenotype in
the evaluated cell type. For example, mineralization capacity may
be evaluated in osteoblasts by means of Alizarin Red S staining of
calcium precipitates. Alternatively, pit assays and tartrate-
resistant acid phosphatase (TRAcP), together with actin ring
staining can be used for exploring osteoclast differentiation and
function. Bone cell-specific markers may also be measured at the
messenger RNA level (using quantitative real-time PCR) or at
protein level (by ELISA or Western blot) (60). As an illustration,
bi-allelic variants in the tissue non-specific alkaline phosphatase
(ALPL) gene, involved in the hypophosphatasia (HPP)
phenotype, were expressed in human osteosarcoma (U2OS)
cells and assessed by measuring ALP activity, as well as the
mineral deposition using Alizarin Red S staining. Results
demonstrated that the location of the variant in the ALP
enzyme structure correlated with the severity of the phenotype
(61). Another example is the comprehensive study of
differentiated osteoclasts from Pls3 knockout and Pls3
overexpressing mouse models. PLS3 variants were found to
influence bone resorption in patients with X-linked early onset
low-turnover osteoporosis (62). Osteoclasts lacking or
overexpressing PLS3 were evaluated using several techniques,
including TRAcP staining and resorption assay; protein
expression analysis by immunohistochemistry and western
blotting; identification of PLS3-binding partners by mass
spectrometry and co-immunoprecipitation; and gene
expression profiling. Finally, authors concluded thatFrontiers in Endocrinology | www.frontiersin.org 13unbalanced PLS3 levels affected osteoclast development and
function by dysregulation of the NFkB pathway (62).
The current limitation of in vitro cell studies is the difficulty
in predicting or interpreting the in vivo behavior since cells
lack critical cell-tissue interactions, mechanical stimuli and
paracrine factors that are pertinent in understanding the
complexity of bone physiology. Hence, cell-based results
should be interpreted with caution when extrapolated to bone
as a whole organ.
Mouse Models: The ‘Gold’ Standard for
Functional Validation
One of the biggest challenges in the validation of a specific SNV
as the cause of a monogenic disease is how to model the genetic
condition. Although there are different strategies for validating
SNVs, the use of a mouse model remains the current gold
standard. Indeed, there are many key advantages and
characteristics favoring this model for the investigation of
heritable conditions, whether they are rare or common. These
include the high degree of genetic and mechanistic conservation
between mice and humans, the high fecundity, and the short life
cycle and gestation period (63). Furthermore, mouse models
allow the consequence of the genetic abnormality to be
determined during intrauterine development, postnatal growth,
adulthood and ageing and following appropriate provocation.
Nevertheless, limitations concerning the use of mouse models
with respect to humans exist. Indeed, some human diseases are
not easily modelled in mice, most of the mouse models used in
research are inbred and do not capture the genetic variation that
exists in humans, and early mutant phenotypes are difficult to
study. Moreover, other limitations of this animal model are
represented by the differences between mouse and human
skeletal structures and dynamics, lack of standardized
protocols for analysis, difficulty of in vivo cell imaging, as well
as statistical and ethical issues (64).
Over the years, genetic bone diseases have been studied by
applying reverse and forward genetic approaches in the mouse
model (65). An important example is represented by mouse
models carrying variants in the Wnt1 (66) and Pls3 (62),
recapitulating low bone mass syndromes according to the
underlying genetic variant.
Before proceeding with the selection or generation of a mouse
model, a primary consideration should be made regarding the
nature of the SNV to be investigated. Firstly, cross-species gene
conservation should be determined, along with the mode of
inheritance of the disease (67). This represents a crucial step in
establishing the design strategy or choice of animal model.
Currently, different methods exist to generate a mouse model,
including gene targeting embryonic stem (ES) cells, conditional
mutagenesis, pronuclear injection-based transgenesis and
CRISPR/Cas9-based genome editing (68). Whichever strategy
is used, the model generated must have a measurable phenotype
that recapitulates the human disease in terms of pathological
characteristics and disease progression.
Once the mouse model has been generated and validated, the
resulting bone phenotype must be assessed, possibly at differentAugust 2021 | Volume 12 | Article 709711
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the presence of bone alterations in small rodents is
microcomputed tomography (µCT), which provides
information on bone mass, density and 3D microarchitecture
(69). To date, µCT allows both ex vivo and in vivo bone analysis.
A quicker phenotyping approach is through classical 2D X-rays.
Unlike µCT, X-ray analysis has low resolution and information is
limited to the presence of gross skeletal abnormalities (69).
Furthermore, ex vivo tissue retrieved from mice can be used to
model bone fragility and bone quality (46) by indentation or
three-point bend and compression testing.
Another essential tool for the investigation of the bone
phenotype at the cellular level is histomorphometry (70).
Serological analysis of several bone formation and resorption
markers can also be performed, including N-Terminal
Propeptide (PINP), bone ALP (bALP), TRAcP, N-terminal
telopeptide (NTx), and C-terminal telopeptide (CTx) (71).
Finally, the mouse model may represent a source of primary
bone cells. This aspect is very important especially if primary
cells from patients are not available due to technical or ethical
issues (72, 73). Overall, the mouse model remains an essential
tool for modeling monogenic bone disorders. The techniques,
benefits, limitations, costs and applications of different
translational model systems are described in more detail in
another review by GEMSTONE Working Group 4 entitled
‘Functional Investigations’ (74).Zebrafish Are an Attractive Model System
for Novel Gene Discoveries
A major bottleneck in translating findings from clinics to lab
benches is the need for a fast and affordable process to test gene
function and drug effects. Zebrafish (Danio rerio) are a small
tropical fish that are highly fecund, have a fully annotated
genome (75) and are relatively cheap to maintain since they
are kept in large shoals. As the vertebrate skeleton is largely
conserved over evolution, zebrafish have osteoblasts, osteocytes,
and osteoclasts (both mono and multi-nucleated) (76) that are
tightly coupled with bone metabolism regulated by similar
pathways (WNT, BMP, parathyroid hormone, etc.) as
described in humans (77). Traditionally, zebrafish have been a
popular model organism in developmental biology as the
translucent embryos are laid extra-maternally making them
very accessible for in vivo imaging experiments. More
importantly, they are easy to manipulate genetically and have
been used for forward genetic screening, gene knockdown (by
micro-injecting antisense RNA morpholinos), or reverse genetic
approaches using targeted endonucleases (gene editing) micro-
injected into one-cell stage zygotes (78, 79). The embryos
develop rapidly; the first cartilage structures appear at 2 days
post fertilization (dpf) in the craniofacial area, whereas dermal
bone elements form as early as 3 dpf. Endochondral ossification
occurs as early as 5 dpf and all these processes can be imaged in
vivo and tracked over time. The notochord initiates its
mineralization process as early as 4 dpf and acts as a templateFrontiers in Endocrinology | www.frontiersin.org 14to give rise to the spinal cord structures comprising of vertebrae
and intervertebral discs (80).
With the recent advent of fast CRISPR/Cas9 protocols and in
combination with the widely available transgenic reporter lines
that drive fluorescent proteins under control of cell-type specific
promoters (such as sp7(osx):GFP [osteoblasts] and col2a1a:
mCherry [chondrocytes]), it is feasible to rapidly test gene
function related to skeletal dysplasias or early mineralization
defects in zebrafish larvae (77, 81, 82) (Figure 3). Furthermore, it
is possible to ablate specific cell types, such as osteoblasts,
chemically by fusing nitroreductase (83) with a fluorescent
protein which is driven by a cell-type specific promoter (e.g.
sp7(osx):mCherry-NTR). This allows temporal control of the
ablation by simply adding NTR to its substrate Nifurpirinol
(antibiotic) in water (84). These and other genetic tools are
valuable to follow de novo osteoblastogenesis and bone
formation in a mutant fish or in a pharmacological setting.
Only in the past few years have the adult skeletal ageing
phenotypes been more thoroughly explored. Adult zebrafish
have extensive endoskeletal (e.g., vertebrae, dermal skull
elements, endochondral jaw elements) and exoskeletal (e.g.,
scales, fin rays, teeth of dermal origin) structures that can be
assessed (80). As the zebrafish skeleton is fully mineralized by 3
months of age, the development of computed tomography (33)
techniques for small samples (µCT) allow detailed quantification
of shape, calcium content and bone volume of the adult zebrafish
skeleton (82, 85). Just as in mammals, the zebrafish bone
architecture responds to glucocorticoids, and loading related to
physical exercise and diet (e.g., high fat, high glucose, ferric
ammonium citrate and high calcitriol) (86–90). Moreover, the
zebrafish exoskeleton (scales and fin rays harboring osteoblasts
and osteoclasts) is easily accessible for experimental procedures
and exhibit the same osteoanabolic gene expression profile (91),
providing a source of bone remodeling tissue that can be used for
bone injury assays (92, 93) and ex vivo multi-well culture
experiments (94).
As demonstrated with the chihuahua (col1a1a) mutant, an OI
model identified during a forward genetic screen, chihuahua
mutant fish have increased mineralized matrix but have brittle
bones that remarkably recapitulate the phenotype exhibited in
affected humans (95). More detailed description of additional
mutants (such as sp7, bmp1a, plod2, entpd5a, mmp9) as bone
disease models have been discussed in recent reviews (77, 82, 85,
96). Since adult fish are kept in large shoals, it is possible to
screen libraries of mutants for specific bone phenotypes using
µCT and then correlate that to the genotype using high-
throughput sequencing approaches (97). Reverse genetic
protocols have improved with CRISPR/Cas9, as specific point
mutations can be introduced in the zebrafish genome (98, 99).
This allows the study of specific genes and gene variants
implicated in HBM, LBM, and other skeletal dysplasia in
zebrafish skeletal models. Hence, combining the power of
genetics and the relative ease of pharmacological manipulation
(in vivo and ex vivo), make zebrafish are an attractive model to
study novel genetic factors discovered in humans.August 2021 | Volume 12 | Article 709711
Formosa et al. Discoveries in Bone Mass DisordersFIGURE 3 | Cross laboratory collaboration to perform functional validation in multiple model systems following a novel gene and variant discovery. Schematic
representation of proposed pipeline to functionally validate a newly identified damaging mutation in a gene. First, evolutionary conservation of the gene and ideally of
the variant should be checked to determine downstream study strategies in the three main model systems relevant to bone: mouse (A), tissue culture cells (B), and
zebrafish (C). These model systems are often utilized sequentially but their use in parallel is likely to enhance output. The main focus of primary functional studies are
gene manipulation (knockdown or knockout) of the whole gene which generate read outs relevant to bone (i.e. CT or mineralization assays). If all three model
systems provide compelling data, the pharmacogenetics phase could provide first data of potential ways to target the new protein by performing high performance
computing in silico drug docking strategies and/or screen compound libraries in multi-well settings (mainly in vitro cultured cells and/or zebrafish ex vivo cultured
scales). Newly identified ‘high confidence’ compounds could then be assessed in adult mice and/or zebrafish for further validation.Frontiers in Endocrinology | www.frontiersin.org August 2021 | Volume 12 | Article 70971115
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OF IN VITRO AND IN VIVO MODELS TO
ACCELERATE PHARMACOLOGICAL
DISCOVERIES
Increasing knowledge of genetic factors involved in bone
metabolism, particularly mechanisms controlling gene
regulation, cell signaling and differentiation, has inspired the
design of drugs to directly target the underlying defect by
inhibiting osteoclastic bone resorption and/or promoting
osteoblastic bone formation. The goal is to identify small
molecular weight compounds that selectively activate or
repress expression of key genes or target specific histone marks
that subsequently alter the corresponding protein level and
signaling pathway. This can be achieved using cells and animal
models as discussed below. Alternatively, the availability of the
ever-growing, highly dimensional omics data that is tissue- and
species-specific has necessitated the need for computational
methods using computer-aided drug design to analyze gene
expression profiles for drug target predictions (100).
An initial mandatory step in drug identification and
preclinical testing of a novel pharmacological compound
involves the use of cells, ranging from in vitro cell cultures
(primary cells, cell lines or iPCS), ex vivo bone explants, and the
more recent 3D cell culture models, to determine the beneficial
and toxic effects of candidate drugs. Additionally, banked
stem cells with a wide variety of genetic backgrounds enable a
more thorough interrogation of the therapeutic options
increasing the possibility of identifying novel drug targets.
Overall, the major challenge of an effective treatment is to
rescue the “healthy” phenotype and, if possible, keep this
improvement permanent.
Studies have also demonstrated the utility of cells in relation
to drug dosing. Li et al. utilized induced primary osteoclasts
to identify the minimal effective concentration exerted by
zoledronic acid for osteoclast suppression with sufficient
alteration in cell adhesion, migration and resorption (101). In
a second example, low doses of odanacatib induced higher anti-
resorptive activity in cultured osteoclasts compared to those
treated with a 100-fold higher dose of the same drug. Exposure
triggered the stimulation of other cysteine proteinases
culminating in increased collagen degradation mimicking that
observed in patients (102).
Despite their limited costs and quick turnaround time, in
vitro cell experiments suffer from several pitfalls in that they
cannot fully capture the complex drug effect and interactions
manifested in vivo. Hence, results obtained in a culture plate
should be interpreted with caution.
The use of mammalian models represents a “mandatory” step
in pharmacological discovery, both prior to or following gene
identification. Animal models present a more holistic and
unbiased set-up for the investigation of known or novel bone
bioactive drug compounds. In vivo compound testing across
different model systems can be performed with varying degrees
of success. Zebrafish are increasingly used for in vivo drug
discovery, drug repurposing, and chemical risk assessment.Frontiers in Endocrinology | www.frontiersin.org 16They bridge the gap between in vitro cellular studies and in
vivo mouse models, and in contrast to mouse models, can be
scaled up for high-throughput drug screening. This is because
zebrafish embryos/larvae (WT or genetically altered) can be
arrayed in 96-well plates exposed to small molecules dissolved
in their water and several replicates can be tested concurrently
increasing statistical power. Additionally, assays are of shorter
duration. Thanks to a rapidly developing skeletal system,
transgenic lines (e.g., sp7(osx), oc2, runx2a, col2a1a) can be
tested for specific skeletal elements and cells, circumventing
the need for sacrificing. In addition, only small drug quantities
are required unlike other mammalian dosing studies (103). A
successful example of an osteogenic drug identified in a zebrafish
chemical screen is Dorsomorphin, a SMAD-dependent BMP
type-II receptor signaling inhibitor specifically named after the
striking phenotypic dorsalization effect in zebrafish embryos
(104), having therapeutic potential to treat fibrodysplasia
ossificans progressive (FOP). Additionally, the larval
superficially located operculum and adult zebrafish scales and
caudal fin (before and after removal) can be used to study the
drug’s effect on osteogenesis. Indeed, prednisolone-treated
zebrafish scales (containing osteoblasts and osteoclasts in their
native environment) reproduces the same glucocorticoid-driven
osteoporotic phenotype as observed in humans (105); the
phenotype is rescued with alendronate (106). Moreover, scales
can be harvested from adult fish and then cultured ex vivo in a
96-well setting which allows testing of various compounds
simultaneously without exposing the individual fish to
potentially harmful pharmacological agents (77, 94).
Zebrafish mutants modelled on rare human bone disorders,
such as OI, can also provide new avenues for drug discovery. An
improvement in the degree of bone mineralization was observed
in chihuahua mutant larvae treated with the chemical
chaperones 4PBA and TUDCA (107), whereas the frilly fins
mutant (defective bmp1a) responded to anti-resorptive therapy,
similar to OI patients with BMP1 mutations (93, 108). In
summary, zebrafish provide a versatile platform for drug
discovery in bone disorders, with pharmacological effects seen
in zebrafish and humans being highly conserved. Thus, any
promising hits are more likely to succeed and can be taken to
higher animal models prior to clinical trials (109).
Rodents, such as mice and rats, have been widely used for
drug testing in common and rare bone diseases. A classic
example is represented by ovariectomized mice or rats, which
have been used to test anti-resorptive (e.g., bisphosphonates,
odanacatib) and anabolic drugs (e.g., teriparatide, anti-sclerostin
monoclonal antibody [Scl-Ab]) (110, 111). Moreover, the use of
transgenic mouse models has also allowed drug discovery studies
to be extended to rare bone diseases facilitating the development
of targeted therapies (112).
The versatility of mouse models has enabled pre-clinical
human studies to progress toward drug development. The
effectiveness and specificity of the candidate compound,
together with the biodistribution within tissues, as well as
clearance and safety can be tested in mice (113). Drugs can be
administered through different routes – systemic or local (114).August 2021 | Volume 12 | Article 709711
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including small molecules, antibodies and RNA interference
(siRNA, shRNA and miRNA).
There are however limitations hindering the use of mice for
drug discovery. The main pitfalls remain the limited number of
compounds that can be tested due to the expenses related to
mouse purchasing and housing, the quantity of drugs used, and
post-treatment analyses (113). Overall, these represent essential
features for translating a potential therapy in the clinical setting
to treat patients. Importantly, most of the discussed aspects can
only be partially tested in other experimental models, including
in vitro and non-vertebrate models, thus making the mouse an
indispensable tool in the drug discovery pipeline.
Another crucial aspect to be considered when using in vivo
animal models in drug discovery is the drug response exhibited
by mice and humans. Hits that prove to be effective in animal
models may fail to show effectiveness in human clinical trials.
Several factors can impact the translational power of
experimental therapies, including the non-reproducibility of
the pre-clinical studies, the technical unfeasibility, and the poor
prediction efficacy of animal models for drug safety in humans
(113, 115). Although several compounds have already been
tested using these approaches, only a very small number of
them have thus far cleared their way to clinical trials.
An important issue to be addressed during a drug
development program is the dose conversion from mice to
humans (116). In fact, extrapolation of the dose from the
animal model in question to humans is a crucial step that has
to take into account different aspects such as varied pharmaco-
kinetic and dynamics, in body weight and surface, and in the
overall physiology existing between the organisms. To overcome
this, different approaches for dose conversion have been
described (117). In particular, the US Food and Drug
Administration released guidelines for industry based on the
dose conversion approach namely “dose by factor” that
represents an empirical method based on the use of the No
Observed Adverse Effect Levels to derive the maximum
recommended starting dose for a clinical trial (118). Other
approaches are specifically applied for targeted model systems.
For example in the case of mouse-human drug conversion, these
are based on the comparison, the similarity, or they can be
pharmacokinetics-guided (118).
Based on these aspects, we therefore propose a three-step
functional study and pharmacological testing pipeline
(Figure 3). Step-1 requires identification of a potentially causal
gene or gene variant that could act as a putative drug target. This
will be used in step-2, where complementary functional studies
will be performed by mouse (A), in vitro cell culture (B), and
zebrafish (C) labs to gather data. These model systems are
commonly tested sequentially following the identification of
potential in silico hits, starting with cells followed by animal
models including teleost or bony fish (zebrafish and medaka) and
mammals. However, their parallel use will increase output and
validation prior to testing in higher animal models and human
clinical trials. If the putative target shows compelling data in
multiple model systems, step-3 will be performed to discoverFrontiers in Endocrinology | www.frontiersin.org 17new compounds that could act on the putative target or its
pathway. In vitro cultured cells and zebrafish will act as primary
complementary testing platforms for therapeutic discovery using
compound(s) that could hypothetically act on the candidate
protein or tractable candidates within the signaling pathway.
These lists of compounds could be derived from in silico drug
docking of synthetic chemical structures (e.g., by using 3D
protein crystal structure), literature-based drug repurposing, or
pre-made commercially available chemical libraries predicted to
act on the signaling pathway. Both zebrafish (larvae or ex vivo
cultured scales) and in vitro systems allow testing of these ‘low-
confidence’ candidates on a (semi-)high throughput scale. When
a sub-set of these compounds shows a pre-defined effect
(validation) in both systems, these ‘higher confidence’
compounds with an osteogenic potential can then proceed to
stage-2 where they can be further validated and tested in the
terrestrial mouse system and/or adult zebrafish (Figure 3). This
pipeline requires cross-discipline collaboration between several
laboratories exercising their expertise. This will speed-up novel
drug discovery, limit false-positive findings (since multiple labs
will validate the findings independently), and reduce unnecessary
animal use.FROM GENETIC DISCOVERIES TO
IMPROVED PATIENT MANAGEMENT IN
RARE BONE DISEASES
The path from discovery of the underlying genetic cause of a
disease through to the development of a clinical therapy is a long
and winding road, but some success stories have been seen
during the recent years in the field of rare bone diseases, such
as targeted therapies for HPP (119), X-linked hypophosphatemic
rickets (120) and achondroplasia (121).
In the field of bone mass disorders, an example of promising
treatment discovery is represented by the OPTA2, as described
above, a rare monogenic disease characterized by bone fragility
despite increased bone mass (122). The phenotype of OPTA2 has
been characterized since the beginning of the 20th century, then
in the 2000s, mutations in the CLCN7 gene were associated with
the disease (123). The in vitro characterization of the pathogenic
variants revealed that CLCN7 mutations negatively affected
osteoclast function, impairing their ability to resorb bone
matrix. Although the number of osteoclasts is normal or even
increased, they were not able to properly acidify the resorption
lacuna and remove mineralized bone matrix (122, 124). The first
animal model for OPTA2 carrying the mouse homolog of the
most frequent and well characterized human CLCN7 mutation
(p.G215R) was created in 2013 (125). Interestingly, the mouse
model not only recapitulated the bone defect but also allowed
deep phenotyping of the disease, revealing its complex
multiorgan involvement (126). To date, there has been no
disease-specific therapy and patients receive only symptomatic
management. Interferon gamma (Actimmune), a promising
non-targeted therapeutic approach, was tested in a phase 2August 2021 | Volume 12 | Article 709711
Formosa et al. Discoveries in Bone Mass Disordersclinical trial (NCT02584608). Unfortunately, despite the
encouraging results obtained from the animal model (127), the
clinical trial in OPTA2 patients was not successful (128).
However, availability of reliable in vitro and in vivo models,
and the known dominant negative nature of the disease-causing
mutation, allowed the development of another innovative
experimental OPTA2 targeted therapy, based on the systemic
delivery of mutation-specific siRNA (73). This experimental
approach has proven to be effective in pre-clinical studies,
rescuing both the skeletal and extra-skeletal defects with no
safety issues (73, 126). This therapy’s clinical development is
expected in the coming years. Therefore, the OPTA2 story is an
example of a “canonical” pipeline in the study of a monogenic
condition that started from the discovery of the disease causing-
mutation and hopefully will end with the clinical development of
targeted therapy.
Unravelling the pathogenic mechanisms underlying rare
monogenic conditions can result in novel treatment options
not only for the specific rare disease but also for more
common disorders. Clear illustrative examples of this are
sclerosteosis and van Buchem disease, two related conditions
arising from mutations affecting the SOST gene which codes the
protein sclerostin (24–27, 129, 130). Sclerostin presented as an
interesting drug target for osteoporosis, not only based on its
function but also because of its expression pattern, being almost
exclusive to bone. Furthermore, it became clear that modulation
of sclerostin concentration and activity affects bone mass, as
indicated by the fact that SOST SNVs are associated with BMD
(131) and that heterozygous carriers for mutations causing
sclerosteosis and van Buchem disease also show an increased
bone mass (132). Clinical trials with a humanized monoclonal
antibody that targets sclerostin (romosozumab) have shown
that the drug increases bone formation and decreases bone
resorption in postmenopausal women with low BMD. In 2019,
romosozumab was approved as an important anabolic treatment
for severe osteoporosis (133). Yet, no long-term data on
romosozumab treatment efficacy or safety is available (134).
Concerns have indeed been raised regarding the increased risk
of cardiovascular events following romosozumab treatment in
older women (135). This is not surprising as canonical WNT
signaling plays a dominant role also in other pathologies,
including heart disease such as myocardial infraction,
cardiovascular remodeling, and congestive heart failure (136).
Elevated sclerostin levels have been positively associated with
increased arterial calcification, a physiological adaptation to
inhibit atherosclerosis development (137). The effect of
sclerostin on vascular pathophysiology has been reviewed in
detail elsewhere (138). However, this brings to light a crucial
caveat in romosozumab treatment that requires further attention
and consideration.
These two examples illustrate that knowledge on pathogenic
mechanisms underlying very rare conditions is crucial for
significant advances in patient care in common disease. Only
hypotheses based on scientific evidence can move the field
forward, as has been demonstrated by the development of
targeted therapies for HPP (119), X-linked hypophosphatemicFrontiers in Endocrinology | www.frontiersin.org 18rickets (120) and achondroplasia (121). The recent advances in
genetic and molecular studies, and access to animal models are
likely to decrease the time interval from disease characterization
to development of targeted therapies. Importantly, the
knowledge obtained from rare monogenic disorders of low and
high bone mass can be used to advance therapeutic discoveries
for more common disorders, especially osteoporosis.
High-throughput sequencing technologies have led to a
significant increase in knowledge in the area of rare hereditary
diseases (139). At the same time, methodological developments
have revolutionized biological science by allowing large-scale
cost-efficient sequencing, frequently integrated with proteomics,
transcriptomic and other omics in a multi-omics approach. On
the other hand, such data can be merged with clinical data,
phenotyping information, imaging data, family history details,
and biochemical results in a multi-source highly integrated data
analysis process (140, 141). Combining all the available data,
bioinformatics methods and Artificial Intelligence approaches
with machine learning, has the potential of creating a paradigm
shift in the gene discovery and consequently, in the entire
diagnostic pathway (142–144).
Studies of rare conditions, more than any other disease, need
structures for data integration between academia and clinical
institutions in order to collect a sufficient number of patients
from which patterns can emerge to underpin valid research
questions. Success in such a collaborative multi-center
approach relies on proper phenotyping with standardized
disease classification, unified and reliable data capture, merging
of data, analyses processes, and storage methods (145, 146). In
addition to this, the quality of machine learning outputs and
bioinformatics methods strictly depends on the quality and
consistency of input data. Considering all the mentioned
points, a goal of the GEMSTONE Working Group 3 is to
create a roadmap for gene discoveries in the context of rare
bone diseases, which requires an established process in close
collaboration with all other GEMSTONE Working Groups
(Figure 4) to assure data quality and impact.CONCLUSIONS
Although individually rare, genetic disorders of the skeleton are
of clinical relevance because of their combined overall frequency
and impact. A correct diagnosis has important implications in
genetic counselling when determining the mode of inheritance
and the recurrence risk in affected families. Furthermore, a
specific diagnosis is helpful in the follow-up and treatment of
the patient, and in predicting long-term outcomes of the
disorder. As highlighted in this review, the clinical and genetic
spectrum of rare disorders of low and high bone mass are still
inadequately understood and novel monogenic disorders still
remain to be discovered. Such disorders have the potential of
providing novel information about molecular pathways
regulating the numerous and only partially known aspects of
bone metabolism. New gene discoveries need to be extensivelyAugust 2021 | Volume 12 | Article 709711
Formosa et al. Discoveries in Bone Mass Disordersvalidated and explored in various in vitro and in vivo
experiments. All this work has the potential to lead to
significant scientific advancements that can be translated into
improved patient care for individuals affected by rare bone
diseases, and also more widely for the millions of individuals
affected by osteoporosis.Frontiers in Endocrinology | www.frontiersin.org 19GEMSTONE WORKING GROUP 3 COST
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